Business
Altimmune to Participate at Two Upcoming Investor Conferences
GAITHERSBURG, Md., May 14, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that members of the Company’s management team will participate and be available for 1x1 meetings at the following investor conferences: H.C. Wainwright 3rd Annual BioConnect Investor Conference (New York, NY)Tuesday, May 20, 2025Fireside Chat at 10:00 a.m. Eastern Time
About this update from Altimmune, Inc.
[{"type":"image","alt":"Altimmune, Inc","displaySize":"","headline":null,"caption":"Altimmune, Inc","className":"","disableSlideshowImg":false,"size":{"original":{"width":150,"height":82,"url":"https://media.zenfs.com/en/globenewswire.com/767e25bad8979b96701d6a099286a009"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/gY.Kxe7ML79dI0xW5370RA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTExNTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/767e25bad8979b96701d6a099286a009","width":150,"height":82}},"lazy":false},{"type":"text","content":"GAITHERSBURG, Md., May 14, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that members of the Company’s management team will participate and be available for 1x1 meetings at the following investor conferences:","length":366,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"H.C. Wainwright 3rd Annual BioConnect Investor Conference (New York, NY)Tuesday, May 20, 2025Fireside Chat at 10:00 a.m. Eastern Time","length":135,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":135,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"Jefferies Global Healthcare Conference (New York, NY)Wednesday, June 4, 2025Fireside Chat at 9:55 a.m. Eastern Time","length":117,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":117,"olType":false},{"type":"text","content":"The sessions will be webcast and can be accessed by visiting the Events section of the Altimmune website.","length":105,"tagName":"p"},{"type":"text","content":"About Altimmune","length":15,"tagName":"p"},{"type":"text","content":"Altimmune is a late clinical-stage biopharmaceutical company focused on developing novel peptide-based therapeutics for liver and cardiometabolic diseases. The Company’s lead program is pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of MASH, obesity, Alcohol Use Disorder (AUD) and Alcohol Liver Disease (ALD). For more information, please visit www.altimmune.com.","length":387,"tagName":"p"},{"type":"text","content":"Follow @Altimmune, Inc. on LinkedInFollow @AltimmuneInc on X","length":61,"tagName":"p"},{"type":"text","content":"Company Contact:Greg WeaverChief Financial OfficerPhone: [email protected]...